About This Tool

The Opdivo (nivolumab) Dosing Calculator is designed for healthcare professionals to quickly determine patient-specific dosing based on approved regimens. It simplifies dose calculation for various oncologic indications by incorporating both flat-dose and weight-based schedules as outlined in the prescribing information.

Outputs Explained

Upon entering the required parameters, the calculator provides the following key outputs for a single administration:

• Calculated Nivolumab Dose (mg): The total milligram dose for the patient.
• Total Volume to Withdraw (mL): The volume of nivolumab (10 mg/mL concentration) to be prepared for infusion.
• Infusion Time: The standard administration time, which is typically 30 minutes.
• Administration Notes: Important instructions regarding required equipment, such as the use of a specific in-line filter.

How to Use the Calculator

1. Select Indication: Choose the appropriate FDA-approved indication from the dropdown menu.
2. Select Dosing Regimen: Pick the corresponding dosing schedule (e.g., 240 mg Q2W, 3 mg/kg Q3W).
3. Enter Patient Weight: If a weight-based regimen is selected, this field will appear. Enter the patient’s weight and select the unit (kg or lbs).
4. Calculate: The tool will display the results. Always verify calculations against the official prescribing information.

Dosing Overview

Nivolumab dosing is specific to the indication and whether it’s used as a monotherapy or in a combination regimen. The two primary dosing strategies are:

• Flat Dosing: A fixed dose, such as 240 mg every 2 weeks or 480 mg every 4 weeks, is administered regardless of patient weight. This is common for many adult indications.
• Weight-Based Dosing: The dose is calculated based on the patient’s body weight, typically in mg/kg. This is common for combination regimens and pediatric indications. For pediatric metastatic colorectal cancer, a maximum dose cap of 240 mg applies.

Switching Regimens

The decision to switch a patient between dosing schedules (e.g., from a 2-week to a 4-week interval) should be based on clinical judgment, patient convenience, and institutional protocols. Always consult the latest prescribing information for guidance on approved dosing frequencies for each indication.

Missed Dose Guidance

This calculator does not provide guidance for missed doses. Refer to the “Dosage and Administration” section of the full Opdivo (nivolumab) Prescribing Information for instructions on managing treatment schedule deviations.

Safety Alerts

This tool is for dose calculation only and does not contain information on dose modifications for adverse reactions, contraindications, or warnings. Opdivo has a BOXED WARNING for immune-mediated adverse reactions, which can be severe or fatal. Healthcare providers must refer to the full Prescribing Information for complete safety data before initiating or managing treatment.

Frequently Asked Questions (FAQ)

1. Why is the patient weight input not always required?
   The weight field only appears for regimens that are weight-based (mg/kg). For flat-dose regimens (e.g., 480 mg), patient weight is not needed for the calculation.
2. Does this calculator provide dose adjustments for toxicity?
   No. This tool calculates standard doses only. Dose withholding or discontinuation for adverse reactions must be managed according to the detailed guidelines in the Prescribing Information.
3. What drug concentration is used for the volume calculation?
   The calculation assumes the standard Opdivo intravenous solution concentration of 10 mg/mL.
4. Can I use pounds (lbs) for patient weight?
   Yes, the tool has a unit selector for kilograms (kg) and pounds (lbs). It performs the necessary conversion automatically.
5. What does “Q2W” or “Q4W” mean?
   “Q2W” means every 2 weeks, and “Q4W” means every 4 weeks. These denote the dosing frequency.
6. Does the tool calculate the dose for ipilimumab in combination regimens?
   No. The tool explicitly notes that it only calculates the nivolumab dose. You must refer to the ipilimumab Prescribing Information for its separate dosing guidelines.
7. Is there a maximum dose calculated for pediatric patients?
   Yes. For the pediatric indication shown (Metastatic Colorectal Cancer), the calculator caps the weight-based dose at a maximum of 240 mg per administration, as per the approved regimen.
8. Is this tool a replacement for the official Prescribing Information (PI)?
   Absolutely not. It is an educational support tool. All calculations and clinical decisions must be verified with the most current, official PI.

References

• OPDIVO (nivolumab) Prescribing Information. U.S. Food and Drug Administration. Rev. March 2024.
• Opdivo (nivolumab) Official Healthcare Professional Site. Bristol Myers Squibb Company.
• Bristol Myers Squibb Medical Information. BMS.
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). National Comprehensive Cancer Network.